These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8607035)

  • 1. In situ cytokine gene transfection using vaccinia virus vectors.
    Lattime EC; Lee SS; Eisenlohr LC; Mastrangelo MJ
    Semin Oncol; 1996 Feb; 23(1):88-100. PubMed ID: 8607035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.
    Mastrangelo MJ; Lattime EC
    Cancer Gene Ther; 2002 Dec; 9(12):1013-21. PubMed ID: 12522440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors.
    Lee SS; Eisenlohr LC; McCue PA; Mastrangelo MJ; Lattime EC
    Cancer Res; 1994 Jul; 54(13):3325-8. PubMed ID: 8012943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution.
    Jackaman C; Nelson DJ
    Cancer Gene Ther; 2010 Jun; 17(6):429-40. PubMed ID: 20150930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.
    Peplinski GR; Tsung AK; Casey MJ; Meko JB; Fredrickson TN; Buller RM; Norton JA
    Cancer J Sci Am; 1996; 2(1):21-7. PubMed ID: 9166494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
    Hoffmann D; Bayer W; Wildner O
    Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards endothelial-cell-directed cancer immunotherapy: in vitro expression of human recombinant cytokine genes by human and mouse primary endothelial cells.
    Ojeifo JO; Su N; Ryan US; Verma UN; Mazumder A; Zwiebel JA
    Cytokines Mol Ther; 1996 Jun; 2(2):89-101. PubMed ID: 9384693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cytokine gene transfer into tumors on host cell infiltration and regression.
    McBride WH; Economou JS; Syljuåsen RG; Parrish C; Hackman D; Latham V; Chiang CS; Dougherty GJ
    Anticancer Res; 1996; 16(3A):1139-43. PubMed ID: 8702225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poxviruses as vectors for cancer immunotherapy.
    Kwak H; Hörig H; Kaufman HL
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.
    Timiryasova TM; Chen B; Fodor I
    J Gene Med; 2001; 3(5):468-77. PubMed ID: 11601760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
    Puhlmann M; Brown CK; Gnant M; Huang J; Libutti SK; Alexander HR; Bartlett DL
    Cancer Gene Ther; 2000 Jan; 7(1):66-73. PubMed ID: 10678358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically marking human cells--results of the first clinical gene transfer studies.
    Cai Q; Rubin JT; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
    Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
    Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of MVA-based therapeutic cancer vaccines.
    Acres B; Bonnefoy JY
    Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.